Day: November 21, 2024

FDA clears XENOVIEW® 3T Chest Coil in GE HealthCare MRI Systems

Written by Customer Service on November 21, 2024. Posted in Public Companies.

Expands accessibility for institutions utilizing GE HealthCare MRI systems DURHAM, NC and LONDON, Nov. 21, 2024 (GLOBE NEWSWIRE) — Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging (“MRI”) of the lungs, announces that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s specialized MRI Chest Coil to now include GE HealthCare 3 Tesla (3T) MRI scanners for the visualization of Xenon-129 nuclei. With this new introduction, the Company now supports Xenon MRI scanning of both clinical and research patients on all three major MRI scanner vendors: GE HealthCare, Philips, and Siemens Healthineers. Polarean’s GE HealthCare compatible XENOVIEW® 3T Chest Coil is a flexible, single-channel,...

Worthington Enterprises Schedules Second Quarter 2025 Earnings Call for December 18

Written by Customer Service on November 21, 2024. Posted in Public Companies.

COLUMBUS, Ohio, Nov. 21, 2024 (GLOBE NEWSWIRE) — Worthington Enterprises, Inc. (NYSE: WOR) will hold its quarterly earnings conference call Wednesday, December 18 at 8:30 a.m. ET. The Company will discuss its fiscal second quarter results, which will be released after the market closes on December 17. Please click here to register for the December 18 live audio webcast or visit IR.worthingtonenterprises.com. For those unable to listen live, a replay will be available in the Investors section of the Company’s website approximately two hours after the completion of the call and will be archived for one year. LIVE CONFERENCE CALL DETAILSDate: Wednesday, December 18, 2024Webcast Link: https://events.q4inc.com/attendee/928120179Starting Time: 8:30 a.m. ETConference ID: 1777337Domestic Participants: 888-330-3567 About...

Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis

Written by Customer Service on November 21, 2024. Posted in Public Companies.

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+)The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent TreatyIRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) — Biomerica, Inc. (NASDAQ: BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease (“GERD”), Crohn’s Disease, and Ulcerative Colitis using its proprietary inFoods® Technology. These patents apply to countries under the European Patent Organization...

O3 Mining Starts Drilling on Globex’s Florence and Cameron Royalty Claims

Written by Customer Service on November 21, 2024. Posted in Public Companies.

ROUYN-NORANDA, Quebec, Nov. 21, 2024 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that O3 Mining Inc. (OIII-TSXV, OIIIF-OTCQX) have initiated a two drill, 8,000 metre exploration program on the Cameron and Florence sections of their Kinebik Project which straddles over 55 kilometres strike of the auriferous Casa Berardi trend in Quebec, northwest of Lebel-sur-Quevillon. The Casa Berardi trend is the location of several large gold deposits including the +5-million-ounce Casa Berardi gold deposit. O3 Mining, in yesterday’s press release, has reported that the current drill...

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn’s Disease and Ulcerative Colitis (UC)

Written by Customer Service on November 21, 2024. Posted in Public Companies.

Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) — Palisade Bio, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preclinical results for PALI-2108, a novel local PDE4 inhibitor prodrug. In recent studies using the Dextran Sulfate Sodium (DSS) colitis mouse model, PALI-2108 demonstrated a dose-dependent effect on key fibrotic pathways, underscoring its potential as an effective treatment for fibrostenotic Crohn’s disease. The data will be presented as part of an invited talk titled, “Detailing...

Stellantis to Participate in Goldman Sachs 16th Annual Industrials & Autos Week

Written by Customer Service on November 21, 2024. Posted in Public Companies.

Stellantis to Participate in Goldman Sachs 16th Annual Industrials & Autos Week AMSTERDAM, November 21, 2024 – Doug Ostermann, Stellantis Chief Financial Officer, will participate in a fireside chat on Wednesday, December 4, 2024, from 1:20 p.m. GMT to 1:55 p.m. GMT at Goldman Sachs 16th Annual Industrials & Autos Week. To watch the live session, visit the following webcast link: https://kvgo.com/gs-industrials-autos-week-2024/stellantis-december Details for watching the fireside chat are also available under the Investors section of the Stellantis corporate website. For those unable to attend the live session, a recorded replay will be accessible following the event. # # # About Stellantis Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is one of the world’s leading automakers aiming to provide...

Summary of the Investor Conference webinar of the 3-month unaudited results of AB Akola Group for the financial year 2024/2025

Written by Customer Service on November 21, 2024. Posted in Public Companies.

On 21 November 2024, AB Akola Group held a webinar, and the company’s CFO, Mažvydas Šileika, presented the financial results for the 3 months of the 2024/2025 financial year. You can view a webinar record on Nasdaq’s YouTube account at:Link to the presentation demonstrated at the webinar: https://www.akolagroup.lt/wp-content/uploads/2024/11/2024.11.21-webinar-2024-2025-3M.pdfMore information: Mažvydas Šileika, CFO of AB Akola GroupMob. +370 619 19 403E-mail m.sileika@akolagroup.lt

SAIC Schedules Third Quarter Fiscal Year 2025 Earnings Conference Call for December 5 at 10 A.M. ET

Written by Customer Service on November 21, 2024. Posted in Public Companies.

RESTON, Va., Nov. 21, 2024 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC) is scheduled to issue its third quarter fiscal year 2025 results before market open on Thursday, December 5, 2024. SAIC executive management will discuss operational and financial results in a conference call beginning at 10:00 a.m. Eastern time, following the issuance of the company’s earnings press release. The conference call will be webcast simultaneously to the public through a link on the Investor Relations section of the SAIC website. The company will only provide webcast access, “dial-in” access will not be available, and a supplemental presentation will be available to the public through links provided on the website. After the call concludes, an on-demand audio replay of the webcast can be accessed on the SAIC Investor...

MARA Holdings, Inc. Completes $1 Billion Offering of 0% Convertible Senior Notes due 2030

Written by Customer Service on November 21, 2024. Posted in Public Companies.

Proceeds to be used primarily to acquire bitcoin and repurchase existing convertible notes due 2026 Fort Lauderdale, FL, Nov. 21, 2024 (GLOBE NEWSWIRE) — MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a global leader in leveraging digital asset compute to support the energy transformation, today announced the closing on November 20, 2024 of its offering of 0.00% convertible senior notes due 2030 (the “notes”). The aggregate principal amount of the notes sold in the offering was $1 billion, which includes $150 million aggregate principal amount of notes issued pursuant to an option to purchase, within a 13-day period beginning on, and including, the date on which the notes were first issued, granted to the initial purchasers under the purchase agreement, which the initial purchasers exercised in full on November 19,...

Warner Music Group Corp. Reports Results for Fiscal Fourth Quarter and Full Year Ended September 30, 2024

Written by Customer Service on November 21, 2024. Posted in Earnings Releases And Operating Results.

Financial HighlightsFull-Year Results Reflect Healthy Performance Across Recorded Music and Music Publishing Continued Strong Growth in Subscription Streaming Underpinned by Healthy Macro Trends Music Publishing Achieves its Fourth Consecutive Year of Double-Digit Revenue Growth Delivered Operating Cash Flow Conversion of 53% in line with GuidanceFor the three months ended September 30, 2024Total revenue increased 3% (the same in constant currency) Digital revenue was flat compared to prior-year quarter Net income was $48 million versus $154 million in prior-year quarter Adjusted OIBDA increased 11% to $353 million versus $317 million in prior-year quarter (the same in constant currency) Cash provided by operating activities decreased 10% to $304 million from $338 million in prior-year quarterFor the twelve months ended September 30,...

Day: November 21, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals